Details of the Drug
General Information of Drug (ID: DMWIALU)
Drug Name |
4-(2-oxo-2H-chromene-3-carboxamido)benzoic acid
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
4-[(2-Oxo-2H-chromene-3-carbonyl)-amino]-benzoic acid; 4-[(2-oxochromen-3-yl)carbonylamino]benzoic acid; 4-{[(2-oxo-2H-chromen-3-yl)carbonyl]amino}benzoic acid; BAS 00518567; AC1MJCO7; 3-carboxamido coumarin, 19; Oprea1_826423; Oprea1_127959; CHEMBL513209; SCHEMBL4389144; BDBM29169; MolPort-000-375-260; ZINC3076649; STL353172; SBB041117; BBL026015; AKOS000269615; MCULE-2534949799; ST50102584; 4-[(2-oxochromene-3-carbonyl)amino]benzoic acid
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 309.27 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||